Philippe Beuzeboc

Philippe Beuzeboc

Auto-generated profile, based on publicly available information

Philippe Beuzeboc

Hôpital Foch Suresnes France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YLYohann Loriot
Yohann Loriot
ABArjun V. Balar
Arjun V. Balar
DPDaniel P. Petrylak
Daniel P. Petrylak
AKArash Rezazadeh Kalebasty
Arash Rezazadeh Kalebasty
PGPetros Grivas
Petros Grivas
STScott T. Tagawa
Scott T. Tagawa
Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2–directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1–3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression. Patients and Methods: TROPHY-U-01 (NCT03547973) is an open-label phase II study that assessed the efficacy and safety of SG (alone or in combinations) in patients with unresectable locally advanced or metastatic UC (mUC). Archival tumor samples collected at enrollment for C1–3 were analyzed for Trop-2 membrane expression by considering histological scores (H-scores; scale 0–300) and the percentage of membrane positive tumor cells at low magnification (4×). The association of Trop-2 with clinical endpoints [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)] was evaluated. Results: In C1–3, tissue was collected from 158 (82%) of 192 treated patients, and 146 (76%) had evaluable Trop-2 data. Trop-2 was highly expressed in tumor samples. The median [interquartile range (IQR)] Trop-2 H-score was 215 (180–246), and the median (IQR) percentage of membrane positive tumor cells was 91% (80–98). Trop-2 expression at any level was observed in 98% of patients. Furthermore, ORR, PFS, and OS benefits were observed across all Trop-2 expression levels. Conclusions: Trop-2 protein is highly expressed in UC, as confirmed by examining tumors from patients enrolled in the TROPHY-U-01 trial. The results indicate that SG demonstrates efficacy in mUC across Trop-2 expression levels.

28 October 2021 in European Journal of Cancer
Verified
Journal Article
Open access
SSSakina Sekkate
Sakina Sekkate
HSHenri-Corto Stoeklé
Henri-Corto Stoeklé
MMMay Mabro
May Mabro
DBDavid Billard
David Billard
TKTitouan Kennel
Titouan Kennel
PBPhilippe Beuzeboc
Philippe Beuzeboc


20 August 2011 in Journal of Clinical Oncology
Verified
Journal Article
Open access
DVDominique Vodovar
Dominique Vodovar
Nicolas MongardonNicolas Mongardon
Nicolas Mongardon
LMLaurence Moachon
Laurence Moachon
MAMichel Arnaout
Michel Arnaout
PBPhilippe Beuzeboc
Philippe Beuzeboc
FPFrédéric Pène
Frédéric Pène

6 April 2011 in European Urology Supplements
Verified
Journal Article
Closed access
NHNadine Houédé
Nadine Houédé
Philippe PourquierPhilippe Pourquier
Philippe Pourquier
PBPhilippe Beuzeboc
Philippe Beuzeboc

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VLVincent Launay-Vacher
Vincent Launay-Vacher
NJNicolas Janus
Nicolas Janus
IRIsabelle Laure Ray-Coquard
Isabelle Laure Ray-Coquard
PBPhilippe Beuzeboc
Philippe Beuzeboc
Juliette THARIATJuliette THARIAT
Juliette THARIAT
GDGilbert Deray
Gilbert Deray
1589 Background: Data still remain scanty on the potential impact of renal insufficiency (RI) on the mortality of cancer patients. The results of 3 clinical studies we conducted (IRMA-2, CANDY and MARS) were pooled. In all 3, methodology and investigators were the same regarding RI. Pooled analysis was thus allowed to study the potential association between RI and overall survival (OS), and to stratify the risk, if any, depending on the GFR Methods: The KDIGO definition and classification of CKD was used. GFR was estimated with the MDRD formula. RI was defined as GFR<60 ml/min/1.73 m². Results: Population included 5908 solid tumor patients (2181 breast, 854 colorectal, 556 lung, 366 ovarian, 293 prostate for the main tumors). Median age 59.2, mean BMI 24.4, 64.0% were women. 70.7% of these patients were alive at the end of the follow-up period of one year. Univariate analysis reported that RI was strongly linked to mortality (p < 0.0001), when analysing together all types of patients and tumors. Furthermo...